Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).

Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).. Crutel, Véronique; Lambert, Estelle; Penelaud, Pierre-François; Albarrán Severo, Cristina; Fuentes, Joaquin; Rosier, Antoine; Hervás, Amaia; Marret, Stéphane; Oliveira, Guiomar; Parellada, Mara; Kyaga, Simon; Gouttefangeas, Sylvie; Bertrand, Marianne; Ravel, Denis; Falissard, Bruno. Journal of autism and developmental disorders. 2021; 51: p.2959-2972. doi:10.1007/s10803-020-04709-8
Article